1887

Chapter 32 : Hepatitis B Virus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Hepatitis B Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch32-1.gif /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch32-2.gif

Abstract:

It has been over 40 years since the discovery of the hepatitis B virus (HBV), and yet the disease it causes remains a major public health challenge. Worldwide, over 240 million people have chronic hepatitis B (CHB), with the majority being in the Asia-Pacific region, and there are almost 800,000 deaths each year as a direct consequence of infection (2). HBV infection is the ninth leading cause of death worldwide. The main public health strategy to control hepatitis B infection for the last 30 years has been primary prevention through vaccination. According to WHO, as of 2013, more than 180 countries have now adopted a national policy of immunizing all infants with hepatitis B vaccine. However, a strategy of secondary prevention is clearly necessary to reduce the risk of long-term complications (cirrhosis, liver failure, and hepatocellular carcinoma) in those individuals who have CHB. The risk of these complications is strongly associated with persistent high-level HBV replication (3–5). Antiviral agents active against HBV are available. The long-term suppression of HBV replication has been shown to prevent progression to cirrhosis and reduce the risk of hepatocellular carcinoma (HCC) and liver-related deaths. However, currently available treatments fail to eradicate the virus in most of those treated, necessitating potentially lifelong treatment. WHO has set targets for both morbidity and mortality. A cure for CHB remains elusive, and a significant research effort is now being directed toward this goal.

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1A
FIGURE 1A

Electron micrography of the various forms found in the blood of HBV-infected persons. The 42-nm virions, both full and empty, can be seen. Within the empty particles, the 27 to 32 nm core structure can be visualized. The excess 22 nm subviral particles and filamentous forms of HBsAg are also present.

The circular double-stranded DNA genome of HBV showing the four main open reading frames (ORFs). The minus (-) and plus (+) DNA strands are marked. The HBV Pol and capped mRNA oligomer at the 5′ end of the (-) and (+) strands, respectively, as well as DR-1 and DR-2 are shown. The space between DR-1 and DR-2 is the “cohesive overlap region.” The plus strand is typically incomplete.

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2A
FIGURE 2A

Biosynthesis of the precore/core, polymerase, envelope, and X proteins from the various HBV transcripts. The two major genomic 3.5-kb transcripts are the larger Precore mRNA, from which the Precore protein (HBeAg) is made, and the smaller pregenomic mRNA that encodes the core and polymerase and is the template for reverse transcription. The single 2.4-kb RNA makes LHBs, while the various 2.1-kb mRNAs translate MHBs and SHBs. The HBx protein is translated from the 0.7-kb mRNA.

The functional domains of the polymerase-reverse transcriptase of HBV See Bartholomeusz et al. ( ) for a more detailed discussion.

Linear, schematic representation of the core protein amino acid residues and the immunodominant B cell and T cell epitopes. See text for details.

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Diagrammatic representation of the epsilon (ε) stem-loop structure of HBV. This is a highly conserved structure within the 10 genotypes of HBV, and the positions of base changes for genotype A2 are shown, as are the common translational precore mutations at G1896A (precore stop codon: UAG) and G1899A.

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Life cycle of HBV. Following attachment, penetration, and uncoating, the viral nucleocapsid is released into the cytosol and transported to the nuclear pore. The relaxed circular DNA is delivered into the nucleus where it is converted into cccDNA, and the viral minichromosome is generated. Transcription of the viral minichromosome produces the genomic and subgenomic HBV mRNA transcripts. Translation of the pregenomic RNA in the cytosol produces the Core and Pol proteins, and, in association with Hsp-60, all are selectively packaged into a replication complex. Within the nucleocapsid, reverse transcription begins. Synthesis of the (+) DNA strand proceeds from the RNA primer to the 5′ end of the (-) DNA strand ( ). The short terminal redundancy of the (-) DNA strand permits the transfer of the 3′ end of the growing short (+) strand from the protein-linked 5′ end to the 3′ end of the minus strand, thereby circularizing the genome and allowing continuation of DNA synthesis, generating the genomic RC DNA molecule with the HBV Pol covalently attached to the 5′ end of the (-) DNA strand. The envelope proteins Pre-S1, Pre-S2, and S are translated at the rough endoplasmic reticulum (ER) and then bud into the lumen of the intermediate compartment. Approximately 50% of the Pre-S1-enriched ER-membrane areas envelope core particles. The HBV virions and subviral particles are then secreted into the extracellular space by usurping the cellular ESCRT pathway. The nucleocapsids can also be transported to the nucleus via an intracellular conversion pathway, thereby increasing the number of nuclear cccDNA molecules.

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Global prevalence of HBsAg, WHO clarifies areas of high, medium, or low endemicity for HBV if the prevalence rates of HBsAg are ≥8%, 2 to 7%, or <2% respectively. (Adapted with permission from Ott et al. [ ]).

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6
FIGURE 6

The host immune response directed against HBV requires coordinated action of both innate immunity and cellular and humoral adaptive immunity to affect both noncytolytic and cytolytic activity. The pathways of noncytolytic clearance are highlighted (see section “Pathogenesis”).

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 7
FIGURE 7

The natural history of chronic hepatitis B, showing relationships between serology, biochemistry, molecular virology (serum and liver compartment), as well as immunological parameters of the innate and adaptive arms.

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 8
FIGURE 8

Nomograms for the predicted risk of (A) liver cirrhosis (low risk <11; moderate risk 11 to 16; high risk ≥17), and (B) HCC (low risk <9; moderate risk 9 to 12; high risk ≥13). These have been developed using identified virologic and host factors that increase risk of complications. The scoring system is outlined in Table 2 . Reproduced with permission from Lee et al. ( ).

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 9
FIGURE 9

HBV DNA genome showing the overlapping open reading frames (ORFs) of POL and S, and, in particular, how the polymerase-envelope overlap can affect each other during the emergence of NA resistance.

Citation: Wong D, Locarnini S, Thompson A. 2017. Hepatitis B Virus, p 713-770. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch32
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819439.ch32
1. Zou H, Chen Y, Duan Z, Zhang H, Pan C. 2012. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 19:e18e25.[PubMed]
2. GBD 2013 Mortality and Causes of Death Collaborators. 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117171.[PubMed]
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678686.[PubMed]
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:6573.[PubMed]
5. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. 2012 High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142:1140.e31149.e3. [PubMed]
6. Norder H, Couroucé AM, Magnius LO. 1994. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198:489503.[PubMed]
7. Stuyver L, de Gendt S, van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. 2000. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 81:6774.[PubMed]
8. Kann ML, Gerlich W,. 2005. Chapter 10, 149181. Structure and Molecular Virology. In Thomas H, Lemon S, Zuckerman A (ed), Viral Hepatitis, 3rd ed. Blackwell Publishing Ltd, Oxford, UK.
9. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M. 2009. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 83:1053810547.[PubMed]
10. Olinger CM, Jutavijittum P, Hübschen JM, Yousukh A, Samountry B, Thammavong T, Toriyama K, Muller CP. 2008. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis 14:17771780.[PubMed]
11. Kramvis A, Kew M, François G. 2005. Hepatitis B virus genotypes. Vaccine 23:24092423.[PubMed]
12. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. 2002. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76:59855992.[PubMed]
13. Owiredu WK, Kramvis A, Kew MC. 2001. Hepatitis B virus DNA in serum of healthy black African adults positive for hepatitis B surface antibody alone: possible association with recombination between genotypes A and D. J Med Virol 64:441454.[PubMed]
14. Funk ML, Rosenberg DM, Lok ASF. 2002. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 9:5261.[PubMed]
15. Kao J-H. 2002. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 17:643650.[PubMed]
16. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. 2006. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44:915924.[PubMed]
17. Kao JH, Chen DS. 2003. Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. Gastroenterology 125:19167. [PubMed]
18. Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, Sung JJ. 2002. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol 97:26292633.[PubMed]
19. Chan HL, Tsang SW, Liew CT, Tse CH, Wong ML, Ching JY, Leung NW, Tam JS, Sung JJ. 2002. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 97:406412.[PubMed]
20. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S Japan HBV Genotype Research Group. 2001. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology 33:218223.[PubMed]
21. Lok AS, Akarca U, Greene S. 1994. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 91:40774081.[PubMed]
22. Ganem D, Schneider RJ. 2001. Hepadnaviridae: the viruses and their replication. Fields Virology 2:29232969.
23. Will H, Reiser W, Weimer T, Pfaff E, Büscher M, Sprengel R, Cattaneo R, Schaller H. 1987. Replication strategy of human hepatitis B virus. J Virol 61:904911.[PubMed]
24. Zoulim F, Seeger C. 1994. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 68:613.[PubMed]
25. Schlicht H-J, Bartenschlager R, Schaller H,. 1991. Chapter 8, 171180. Biosynthesis and enzymatic functions of the hepadnaviral reverse transcriptase. In McLachlan A (ed), Molecular Biology of the Hepatitis B Virus. CRC Press, Boca Raton, FL.
26. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:2960.[PubMed]
27. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:10471058.[PubMed]
28. Chu CM, Liaw YF. 1987. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 92:220225.[PubMed]
29. Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, Zentgraf H. 2001. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 307:183196.[PubMed]
30. Chen HS, Kew MC, Hornbuckle WE, Tennant BC, Cote PJ, Gerin JL, Purcell RH, Miller RH. 1992. The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol 66:56825684.[PubMed]
31. Hadziyannis SJ, Vassilopoulos D. 2001. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34:617624[PubMed]
32. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. 1990. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 87:65996603.[PubMed]
33. Scaglioni PP, Melegari M, Wands JR. 1997. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 71:345353.[PubMed]
34. Hadziyannis S. 1995. HBeAg-negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1:7l5.
35. Hunt CM, McGill JM, Allen MI, Condreay LD. 2000. Clinical relevance of hepatitis B viral mutations. Hepatology 31:10371044.[PubMed]
36. Locarnini S, Shaw T, Dean J, Colledge D, Thompson A, Li K, Lemon SM, Lau GG, Beard MR. 2005. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. J Clin Virol 32:11321. [PubMed]
37. Bartholomeusz A, Schaefer S. 2004. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol 14:316.[PubMed]
38. Salfeld J, Pfaff E, Noah M, Schaller H. 1989. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol 63:798808.[PubMed]
39. Colucci G, Beazer Y, Cantaluppi C, Tackney C. 1988. Identification of a major hepatitis B core antigen (HBcAg) determinant by using synthetic peptides and monoclonal antibodies. J Immunol 141:43764380.[PubMed]
40. Milich DR, McLachlan A, Moriarty A, Thornton GB. 1987. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol 139:12231231.[PubMed]
41. Bertoletti A, Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Fowler P, Vitiello A, Chesnut RC, Fiaccadori F, Farrari C. 1993. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 67:23762380.[PubMed]
42. Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, Ferrari C, Chisari FV. 1993. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 177:751762.[PubMed]
43. Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, Pilli M, Fowler P, Giuberti T, Chisari FV. 1991. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 88:214222.[PubMed]
44. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325329.[PubMed]
45. Sureau C, Salisse J. 2013. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 57:985994.[PubMed]
46. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. 1994. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68:81028110.[PubMed]
47. Sobotta D, Sominskaya I, Jansons J, Meisel H, Schmitt S, Heermann KH, Kaluza G, Pumpens P, Gerlich WH. 2000. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol 81:369378.[PubMed]
48. Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P, Chisari FV. 1985. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228:11951199.[PubMed]
49. Tron F, Degos F, Brechot C, Courouce A-M, Goudeau A, Marie F-N, Adamowicz P, Saliou P, Laplanche A, Benhamou J-P, Girard M. 1989. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences. J Infect Dis 160:199204.[PubMed]
50. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S. 2014. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146:10701083.[PubMed]
51. Urban S, Bartenschlager R, Kubitz R, Zoulim F. 2014. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147:4864.[PubMed]
52. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. 1986. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 137:315322.[PubMed]
53. Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, Hantz O, Protzer U. 2011. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55:9961003.[PubMed]
54. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. 2009. Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581592.[PubMed]
55. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M. 2009. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 106:1997519979.
56. Benhenda S, Ducroux A, Rivière L, Sobhian B, Ward MD, Dion S, Hantz O, Protzer U, Michel ML, Benkirane M, Semmes OJ, Buendia MA, Neuveut C. 2013. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol 87:43604371.[PubMed]
57. Minor MM, Slagle BL. 2014. Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system. Viruses 6:4683702. [PubMed]
58. Guo L, Wang X, Ren L, Zeng M, Wang S, Weng Y, Tang Z, Wang X, Tang Y, Hu H, Li M, Zhang C, Liu C. 2014. HBx affects CUL4-DDB1 function in both positive and negative manners. Biochem Biophys Res Commun 450:14921497.[PubMed]
59. Hodgson AJ, Hyser JM, Keasler VV, Cang Y, Slagle BL. 2012. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology 426:7382.[PubMed]
60. Tang KF, Xie J, Chen M, Liu Q, Zhou XY, Zeng W, Huang AL, Zuo GQ, Wang Y, Xiang R, Ren H. 2008. Knockdown of damage-specific DNA binding protein 1 (DDB1) enhances the HBx-siRNA-mediated inhibition of HBV replication. Biologicals 36:177183.[PubMed]
61. Leupin O, Bontron S, Schaeffer C, Strubin M. 2005. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. J Virol 79:42384245.[PubMed]
62. Koike K, Tsutsumi T, Fujie H, Shintani Y, Kyoji M. 2002. Molecular mechanism of viral hepatocarcinogenesis. Oncology 62 (Suppl 1):2937.[PubMed]
63. Rossner MT. 1992. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 36:101117.[PubMed]
64. Esteller M. 2011. Non-coding RNAs in human disease. Nat Rev Genet 12:861874.[PubMed]
65. Tian Y, Yang W, Song J, Wu Y, Ni B. 2013. Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol 33:28102816.[PubMed]
66. Zhang XD, Wang Y, Ye LH. 2014. Hepatitis B virus X protein accelerates the development of hepatoma. Cancer Biol Med 11:18290. [PubMed]
67. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Stürzbecher HW, Hoeijmakers JH, Harris CC. 1995. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 55:60126016.[PubMed]
68. Huang J, Kwong J, Sun EC, Liang TJ. 1996. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol 70:55825591.[PubMed]
69. Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ. 1999. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J Virol 73:723140. [PubMed]
70. Wieland SF, Chisari FV. 2005. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 79:93699380.[PubMed]
71. Beck J, Nassal M. 2007. Hepatitis B virus replication. World J Gastroenterol 13:4864. [PubMed]
72. Schulze A, Gripon P, Urban S. 2007. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46:17591768.[PubMed]
73. Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W. 2014. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol 88:32733284. [PubMed]
74. Meier A, Mehrle S, Weiss TS, Mier W, Urban S. 2013. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology 58:3142.[PubMed]
75. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C. 1995. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213:292299.[PubMed]
76. König A, Döring B, Mohr C, Geipel A, Geyer J, Glebe D. 2014. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol 61:867875.[PubMed]
77. Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M. 2013. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 58:861867.[PubMed]
78. Rabe B, Vlachou A, Panté N, Helenius A, Kann M. 2003. Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci USA 100:98499854.[PubMed]
79. Bock CT, Schranz P, Schröder CH, Zentgraf H. 1994. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 8:215229.[PubMed]
80. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. 1995. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69:33503357.[PubMed]
81. Königer C, Wingert I, Marsmann M, Rösler C, Beck J, Nassal M. 2014. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA 111:E4244E4253.[PubMed]
82. Bartenschlager R, Schaller H. 1992. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 11:34133420.[PubMed]
83. Stieler JT, Prange R. 2014. Involvement of ESCRT-II in hepatitis B virus morphogenesis. PLOS ONE 9:e91279. [PubMed]
84. Votteler J, Sundquist WI. 2013. Virus budding and the ESCRT pathway. Cell Host Microbe 14:232241. [PubMed]
85. Lambert C, Doring T, Prange R. 2007. Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and gamma 2-adaptin. J Virol 81:90509060. [PubMed]
86. Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K. 2005. G to A hypermutation of hepatitis B virus. Hepatology 41:626633.[PubMed]
87. Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V. 2006. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 13:427434.[PubMed]
88. Girones R, Miller RH. 1989. Mutation rate of the hepadnavirus genome. Virology 170:595597.[PubMed]
89. Günther S, Fischer L, Pult I, Sterneck M, Will H. 1999. Naturally occurring variants of hepatitis B virus. Adv Virus Res 52:25137.[PubMed]
90. Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. 2003. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Clin Pathol 163:24412449. [PubMed]
91. Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW, Su IJ. 2009. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 49:19621971.[PubMed]
92. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J, Kliem V, Müller R, Thomas HC, Manns MP. 1996. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24:489493.[PubMed]
93. Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR. 2008. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 13:161175.[PubMed]
94. Lok AS, McMahon BJ Practice Guidelines Committee, American Association for the Study of Liver Diseases. 2001. Chronic hepatitis B. Hepatology 34:12251241.[PubMed]
95. Maynard JE. 1990. Hepatitis B: global importance and need for control. Vaccine 8 (Suppl):S18S20.[PubMed]
96. Mast EE, Alter MJ, Margolis HS. 1999. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 17:17301733.[PubMed]
97. Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. 2000. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 31:763768.[PubMed]
98. Schalm SW, Thomas HC, Hadziyannis SJ. 1990. Chronic hepatitis B. Prog Liver Dis 9:443462.[PubMed]
99. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. 1999. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 179:775782.[PubMed]
100. Thompson AJV, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, Chen RYM, Demediuk B, Shaw G, Bell SJ, Watson KJR, Locarnini SA, Desmond PV. 2007. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 22:10781085.[PubMed]
101. Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio PL Italian Hospitals’ Collaborating Group. 2008. Chronic hepatitis B in Italy: new features of an old disease—approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis 46:110113.[PubMed]
102. Chowdhury A, Santra A, Chakravorty R, Banerji A, Pal S, Dhali GK, Datta S, Banerji S, Manna B, Chowdhury SR, Bhattacharya SK, Mazumder DG. 2005. Community-based epidemiology of hepatitis B virus infection in West Bengal, India: prevalence of hepatitis B e antigen-negative infection and associated viral variants. J Gastroenterol Hepatol 20:17121720[PubMed]
103. Apostolov K, Bauer DJ, Selway JW, Fox RA, Dudley FJ, Sherlock S. 1971. Australia antigen in urine. Lancet 1:12741275.[PubMed]
104. Kidd-Ljunggren K, Holmberg A, Bläckberg J, Lindqvist B. 2006. High levels of hepatitis B virus DNA in body fluids from chronic carriers. J Hosp Infect 64:352357.[PubMed]
105. Qian W-P, Tan Y-Q, Chen Y, Peng Y, Li Z, Lu G-X, Lin M-C, Kung H-F, He M-L, Shing L-K. 2005. Rapid quantification of semen hepatitis B virus DNA by real-time polymerase chain reaction. World J Gastroenterol 11:53855389.[PubMed]